Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancersopen access
- Authors
- Kim, Jimi
- Issue Date
- Dec-2023
- Publisher
- MDPI
- Keywords
- oncogenic KRAS; cancer therapy; RNA therapeutics; RNAi; CRISPR-Cas; mRNA vaccine
- Citation
- INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.24, no.23
- Journal Title
- INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Volume
- 24
- Number
- 23
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/90414
- DOI
- 10.3390/ijms242316933
- ISSN
- 1661-6596
1422-0067
- Abstract
- Activating mutations in KRAS are highly relevant to various cancers, driving persistent efforts toward the development of drugs that can effectively inhibit KRAS activity. Previously, KRAS was considered 'undruggable'; however, the recent advances in our understanding of RNA and nucleic acid chemistry and delivery formulations have sparked a paradigm shift in the approach to KRAS inhibition. We are currently witnessing a large wave of next-generation drugs for KRAS mutant cancers-nucleic acid-based therapeutics. In this review, we discuss the current progress in targeting KRAS mutant tumors and outline significant developments in nucleic acid-based strategies. We delve into their mechanisms of action, address existing challenges, and offer insights into the current clinical trial status of these approaches. We aim to provide a thorough understanding of the potential of nucleic acid-based strategies in the field of KRAS mutant cancer therapeutics.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/90414)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.